Ajanta Pharma launches generic asthma drug in US market
New Delhi, Nov 16 : Ajanta Pharma today said it has launched generic version of Singulair granules, used in the treatment of asthma, in the US market.
The company in a filing to BSE said Ajanta Pharma US Inc has launched montelucast sodium granules, a generic version of Merck & Co, Inc's Singulair granules, in the US market.
The granules have been launched in cartons containing 30 individual sachets.
"The approval and launch of the granules are part of an ever growing portfolio that Ajanta Pharma has developed for the US market", the drug firm said.
Ajanta has so far received five abbreviated new drug application (ANDA) approvals from the US Food and Drug Administration (USFDA).
An additional 19 ANDAs are pending approval from the US FDA.
Shares of Ajanta Pharma today ended at Rs 1,334.55 apiece on the BSE, down 4.02 per cent from previous close.
The company in a filing to BSE said Ajanta Pharma US Inc has launched montelucast sodium granules, a generic version of Merck & Co, Inc's Singulair granules, in the US market.
The granules have been launched in cartons containing 30 individual sachets.
"The approval and launch of the granules are part of an ever growing portfolio that Ajanta Pharma has developed for the US market", the drug firm said.
Ajanta has so far received five abbreviated new drug application (ANDA) approvals from the US Food and Drug Administration (USFDA).
An additional 19 ANDAs are pending approval from the US FDA.
Shares of Ajanta Pharma today ended at Rs 1,334.55 apiece on the BSE, down 4.02 per cent from previous close.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.